RIEFLIN WILLIAM JL 4

What Happened

• William Rieflin, a director of Lyell Immunopharma (LYEL), was granted 9,250 derivative shares on 2026-06-10. The filing shows an acquisition price of $0.00 (no cash paid). This is an award/grant (code A) rather than a market purchase or sale.

Key Details

• Transaction date: 2026-06-10; Form 4 filed: 2026-06-12 (timely).
• Amount: 9,250 derivative shares granted at $0.00 per share.
• Shares owned after transaction: not specified in the provided filing.
• Footnote: Vesting occurs on the earlier of (a) the date of Lyell’s next annual stockholders’ meeting following June 10, 2026 (or immediately before if the director’s service ends because of non‑re-election), or (b) the first anniversary of June 10, 2026 — subject to continuous service through that date.
• Transaction type: Award/Grant of derivative securities (not an exercise or sale).

Context

• This is a grant of derivative securities that will vest within about a year (or sooner at the next annual meeting), so the shares are not immediately liquid. For a dollar value, multiply 9,250 by Lyell’s market price on or after 2026-06-10.
• The filing does not indicate an immediate sale (no cashless exercise) or any 10b5-1/tax‑withholding flags. This is a standard director award and should be interpreted as compensation/retention, not a direct market signal.